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ABSTRACT
Symptoms (pain, fatigue, sleep disturbance, depression, and anxiety) in inflammatory
bowel disease (IBD) are associatedwith reducedquality of life. Understanding how IBD
symptoms cluster and the clinical and demographic factors associated with symptom
clusters will enable focused development of symptommanagement interventions. The
study purposes were to (i) identify symptom cluster membership among adults with
IBD and (ii) examine associations between demographic (age, gender, race/ethnicity,
and education) and clinical factors (smoking status, time since diagnosis, medication
type, IBD type, disease activity), and membership in specific symptom cluster groups.
Weconducted a retrospective studyof data from theCrohn's andColitis Foundation of
America's (CCFA) Partners Cohort and used Patient Reported OutcomeMeasurement
Information System (PROMIS) measures to measure pain interference, fatigue, sleep
disturbance, anxiety, and depression. The sample included 5,296 participants with IBD
(mean age 44, 72% female). In latent class analysis (LCA), four groups of participants
were identified based on symptoms: “low symptom burden” (26% of sample), “high
symptom burden” (38%), “physical symptoms” (22%), and “psychological symptoms”
(14%). In multinomial regression, female gender, smoking, corticosteroids, Crohn's
disease, and active disease state were associated with membership in the high
symptom burden group. Additional research is needed to test interventions that may
be effective at reducing symptom burden for individuals with IBD.
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1 | SYMPTOM CLUSTERS IN ADULTS WITH
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease (IBD) primarily includes Crohn's disease
and ulcerative colitis, afflicts 1.4 million people in the United States,
and has increasing incidence rates worldwide (Molodecky et al., 2012).
IBD follows an unpredictable course associated with periods of active
disease and remission and can lead to complications that lead to the
escalation of therapy, hospitalization, and surgery (Loftus, 2004).
IBD is associated with many signs and symptoms, including
diarrhea, fever, reduced appetite, weight loss, pain, and fatigue. The
most prevalent and distressing symptoms experienced by people
with IBD are pain, fatigue, sleep disturbance, depression, and
anxiety. Between 58.7% and 85.5% of people with IBD experience
pain (Ghosh & Mitchell, 2007; Haapamaki, Turunen, Roine, Farkkila,
& Arkkila, 2008; Haapamaki, Turunen, Roine, Farkkila, & Arkkila,
2009; Horvath et al., 2012; Magro et al., 2009); 41–48% experience
fatigue (van Langenberg & Gibson, 2010); 49–77% experience sleep
disturbance (Graff et al., 2011); 25–61% report depressive
symptoms (Guthrie et al., 2002; Magro et al., 2009; Vidal et al.,
2008; Zhang et al., 2013); and 31–44% report anxiety (Guthrie et al.,
2002; Vidal et al., 2008).
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People with IBD rate symptoms as major concerns and perceive
symptoms to be more distressing than fecal incontinence and the
potential development of colon cancer (Czuber-Dochan, Dibley, Terry,
Ream, & Norton, 2012; de Rooy et al., 2001; Stjernman, Tysk, Almer,
Strom, & Hjortswang, 2010). People with IBD are often embarrassed
by symptoms that affect career plans and restrict social life (Devlen
et al., 2014). Symptom burden contributes to decreased work
productivity (Haapamaki et al., 2009; Magro et al., 2009), decreased
ability to participate in leisure activities (Ghosh & Mitchell, 2007;
Haapamaki et al., 2009), and reduced quality of life (Ghosh & Mitchell,
2007; Haapamaki et al., 2008).
Symptoms are more common during periods of active disease, but
they frequently persist during remission (Ghosh & Mitchell, 2007;
Graff et al., 2011; Kurina, Goldacre, Yeates, & Gill, 2001; van
Langenberg & Gibson, 2010), when intestinal inflammation and the
associated fever, rectal bleeding, abnormal stool frequency, and fecal
urgency are quiescent (Panaccione, Colombel, Louis, Peyrin-Biroulet,
& Sandborn, 2013; Travis et al., 2011). Even during remission,
symptoms continue to rank as a top disease-related concern in IBD
(Keeton, Mikocka-Walus, & Andrews, 2015).
Although past research conducted with people who have IBD
focused on single symptoms, symptoms co-occur. For example,
depression and anxiety were associated with pain (Schirbel et al.,
2010), and sleep disturbance was associated with fatigue, depression,
anxiety, and abdominal pain (Ananthakrishnan, Long, Martin, Sandler,
& Kappelman, 2013; Banovic, Gilibert, & Cosnes, 2010; Banovic,
Gilibert, Jebrane, & Cosnes, 2012; Benhayon et al., 2013; Graff et al.,
2013; Jelsness-Jorgensen, Bernklev, Henriksen, Torp, &Moum, 2011).
In other chronic inflammatory conditions, such as heart disease and
cancer, symptoms occur in clusters (Aktas, Walsh, & Rybicki, 2010;
Dodd,Miaskowski, & Lee, 2004; Fan, Filipczak, &Chow, 2007), defined
as two or more related symptoms that co-occur (Fan et al., 2007).
However, little is known about symptom clusters among people with
IBD or the demographic and clinical factors that may be associated
with symptom clusters.
Demographic factors associated with individual symptoms in IBD
include younger age (Bager et al., 2012) and female gender (Larsson,
Loof, Ronnblom, & Nordin, 2008; Romberg-Camps et al., 2010).
Although the potential associations between race and ethnicity and
symptoms have not been examined in people with IBD, differences in
racial and ethnic group members’ perceptions of IBD may influence
symptom reporting. For example, these may include differences in
attributing disease activity to stress and in informing their support
network about their diagnosis (Finlay, Basu, & Sellin, 2006). Education
level is not associated with fatigue (Czuber-Dochan, Ream, & Norton,
2013), but higher educational attainment is associatedwith depression
in IBD (Fuller-Thomson & Sulman, 2006).
Evidence on links between clinical factors and symptoms is mixed.
Longer disease duration and Crohn's disease (compared to ulcerative
colitis; Guthrie et al., 2002) are associated with increased symptoms
(Mussell, Bocker, Nagel, & Singer, 2004). In contrast to people who
have ulcerative colitis, people who smoke, and have Crohn's disease
may experience fewer symptoms (Mahid, Minor, Soto, Hornung, &
Galandiuk, 2006; Parkes, Whelan, & Lindsay, 2014). IBD medications
are associated with both increased and decreased symptoms
(Haapamaki et al., 2009; Louis et al., 2013). While remission status
is associated with reduced symptoms, symptoms can persist during
remission (Keeton et al., 2015).
Improved understanding of the nature of symptom clusters and
their clinical and demographic correlates is needed to support
future interventions focused on managing symptom clusters. This
is crucial because treating single symptoms (e.g., depression) may
not improve other related symptoms (e.g., sleep disturbance or
fatigue; Morrow et al., 2003; Taylor, Walters, Vittengl, Krebaum, &
Jarrett, 2010). Understanding modifiable and non-modifiable risk
factors for symptom clusters will also assist in targeting future
interventions.
1.1 | Purpose
The purposes of this study were to (i) identify symptom cluster
membership groups (for symptoms of pain, fatigue, sleep disturbance,
depression, and anxiety) among adults with IBD and (ii) examine the
associations between demographic (age, gender, race/ethnicity, and
education) and clinical factors (smoking status, time since diagnosis,
medication type, disease activity), and membership in specific
symptom clusters.
2 | METHODS
2.1 | Design
We conducted a retrospective analysis of cross-sectional data
obtained from the Crohn's and Colitis Foundation of America
(CCFA) Partners Cohort that includes adults who had self-reported
IBD and responded to a web-based survey. The CCFA Partners began
in 2011 and has ongoing enrollment. It includes participants from all 50
United States, multiple US territories, and several additional countries.
Data are collected via an internet survey every 6months. Full details of
the cohort and the data collection methods are reported elsewhere
(Long et al., 2012). The University of North Carolina Chapel Hill
institutional review board (IRB) approved the original study, and all
participants provided written informed consent. The IRB at Yale
University determined that the present analysis was exempt due to the
use of de-identified data.
2.2 | Sample
The CCFA Partners Cohort included 14,314 participants. Participants
were 18 years of age or older and had self-reported diagnoses of IBD
(Crohn's disease or ulcerative colitis/indeterminate colitis). In a
validation study of 184 CCFA Partners participants, 97% of the self-
reported IBD diagnoses were confirmed by a physician (Randall et al.,
2013). We excluded participants who had ostomies or j-pouches
because the clinical disease activity indices were not created to assess
disease activity after these surgical alterations.
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Power analysis methods have yet to be standardized for latent
class analysis (LCA), but LCA experts suggest that 100–300
participants are needed to run an LCA model (Collins & Lanza, 2010;
Wurpts &Geiser, 2014). The study sample included 5,296 participants;
therefore, the sample size was adequate for LCA.
2.3 | Variables and measures
2.3.1 | Demographic and clinical characteristics
Demographic and clinical characteristics were obtained by self-report.
Demographic variables included age, race/ethnicity (non-Hispanic
white or other) and gender (male or female). Clinical variables included
smoking status (never or current/past), duration of IBD (years), current
IBD medications (corticosteroids, 5-ASAs, immunomodulators, bio-
logics), and IBD type (Crohn's disease or ulcerative colitis/indetermi-
nate colitis), and clinical remission (yes/no). Self-reported disease
activity indices including the Short Crohn's Disease Activity Index
(SCDAI; Thia, Faubion, et al., 2011) and the Simple Clinical Colitis
Activity Index (SCCAI; Thia, Loftus, et al., 2011; Walmsley, Ayres,
Pounder, & Allan, 1998) were used to differentiate active disease from
remission. These clinical indices elicit frequency of bowel movements,
the presence of blood in the stool, extra-intestinal manifestations of
IBD, and overall health. Scores of <150 on the Short Crohn's Disease
Activity Index (Thia, Faubion, et al., 2011) and ≤2 on the Simple Clinical
Colitis Activity Index (Walmsley et al., 1998) were defined as clinical
remission (Thia, Faubion, et al., 2011).
2.3.2 | Symptoms
Pain interference, fatigue, sleepdisturbance,depression, andanxietywere
measured with the Patient Reported Outcomes Measurement Informa-
tion System (PROMIS) from the National Institutes of Health. These
symptoms were selected because they are the most common and
distressing symptoms experienced by people with IBD (Ananthakrishnan
et al., 2013; Banovic et al., 2010, 2012; Benhayon et al., 2013; Graff et al.,
2013; Jelsness-Jorgensenetal., 2011).PROMISwasdevelopedwith item-
response theory, a method that permits for the reduction of a large
number of items into a concise unidimensional measure that is highly
reliable, precise, and retains statistical power (Fries, Bruce, & Cella, 2005).
Four-item PROMIS short forms were used to elicit each of the
symptoms as occurring over the past 7 days. PROMIS items employ
5-point Likert scales that range from not at all to very much, with the
exception of the pain interference items that include a score of zero for
no pain in addition to the 5-point Likert scale. PROMIS measures are
scored on a normalized t-score based on the general population, with
50 as the mean and 10-point standard deviation increments (National
Institutes of Health, 2013).
2.3.3 | Pain interference
Items elicited responses about how much pain interfered with the
ability to work in the home, perform chores, participate in social
activities, and do day-to-day activities. This scale has concurrent
validity with the Medical Outcomes Study Short-Form 36 (SF-36)
Bodily Pain Scale (Amtmann et al., 2010).
2.3.4 | Fatigue
Fatigue items elicit frequency, duration, intensity, and interference
characteristics (Cella et al., 2010). The fatigue scale is valid and reliable
and has comparable performance to the SF-36 Vitality scale and the
Functional Assessment of Chronic Illness Therapy-Fatigue scale (Cella
et al., 2010).
2.3.5 | Sleep disturbance
Sleep disturbance items are designed to elicit sleep quality, the extent
to which sleep was refreshing, difficulty falling asleep, and sleep
problems (National Institutes of Health, 2013). The PROMIS Sleep
Disturbance scale is valid compared to the Pittsburgh Sleep Quality
Index and is better able to discriminate between levels of sleep
disturbance (Yu et al., 2011).
2.3.6 | Depression
Depression items elicit frequency of feeling depressed, hopeless,
worthless, and helpless (Teresi et al., 2009). The PROMIS depression
scale is comparable to legacy depressionmeasures, and the absence of
somatic items supports its appropriateness for use in chronic health
conditions (Pilkonis et al., 2011).
2.3.7 | Anxiety
Anxiety items elicit responses about fear, ability to focus on anything
other than anxiety, worries, and feeling of unease (National Institutes
of Health, 2013). The anxiety measure is valid compared to legacy
anxiety measures (Pilkonis et al., 2011).
2.3.8 | Symptom cut-off scores
Wedichotomized the symptom scores to indicate presence or absence
of the symptom because LCA requires the use of categorical indicator
variables. Each of the symptom scores was categorized as present
(≥t-score of 50) or absent (<50) because scores of 50 or higher indicate
the presence of a clinically significant symptom (Cella et al., 2014;
National Institutes of Health, 2013).
2.4 | Statistical analysis
Data were described using distributions, means, medians, standard
deviations, and frequencies as appropriate. We compared individual
symptoms and disease activity using chi-square analysis and used
LCA, a clustering approach that classifies subgroups of people into
mutually exclusive and exhaustive groups based on the presence
or absence of a characteristic, to determine symptom cluster
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membership (Lanza, Collins, Lemmon, & Schafer, 2007; Vermunt &
Magidson, 2004). We used SAS 9.4 with the PROC LCA & LTA (Lanza,
Dziak, Huang, Wagner, & Collins, 2015) add-on for SAS from the
Methodology Center at Pennsylvania State to conduct the analysis.
Significance was set at p < .05.
There are two conceptual views of symptom clusters: the grouping
of variables (variable-oriented) and the grouping of people (person-
oriented; Maliski, Kwan, Elashoff, & Litwin, 2008). Variable-oriented
approaches, such as factor analysis, focus on identifying relationships
between variables, and researchers assume that these relationships
are stable across the population. Person-oriented approaches, such as
latent class and cluster analyses, are used to identify subgroups of
people who exhibit similar patterns of characteristics. Common
person-oriented clustering methods include latent class and cluster
analysis (Bergman&Trost, 2006; Collins & Lanza, 2010; Conley, 2016).
The person-oriented approach is particularly useful in uncovering
subgroups in heterogeneous populations because the structure of the
variables does not have to remain constant across the population
(Magnusson, 2003). Because people with IBD are a heterogeneous
population, we used LCA to identify symptom cluster group
membership.
The symptoms of pain interference, fatigue, depression, anxiety,
and sleep disturbance were categorical indicator variables in the LCA
model. We ran models with one, two, three, four, and five classes
because these were the number of plausible groups, given the use of
five symptom variables. To determine the optimal fit of latent classes
with our data, model fit statistics were the Akaike information criterion
(AIC; Akaike, 1987), and the Bayesian information criterion (BIC;
Schwartz, 1978). AIC and BIC are both relative fit statistics; therefore,
no single number indicates best fit. Model fit is determined relative to
other models, and lower numbers indicate better fit. We also reported
goodness of fit G2 fit statistic, an absolute model fit statistic that does
not take the other models into consideration. The goodness of fit G2 fit
statistic follows a chi-square distribution. As is standard with LCA, we
also took into account parsimony and interpretability when selecting
the final model.
To interpret the final model, we used class prevalences and item-
response probabilities. Latent class prevalences provide the proportion
of people belonging to each class. Item-response probabilities reflect
the probability that a group will endorse a particular response. Item-
response probabilities range from 0 to 1, and larger numbers indicate a
higher probability of a symptom occurring within a particular group
(Collins & Lanza, 2010).
To explore the associations between demographic (age, gender,
race/ethnicity, education level) and clinical characteristics (smoking
status, time since diagnosis, IBD medications, IBD type, disease
activity), and symptom cluster membership, multinomial regression
with backward selection using a logit link function was used.
Multinomial regression is similar to logistic regression but allows for
multiple categorical non-ordered outcomes. All demographic and
clinical factors were added into the model, and characteristics that
were not statistically significantly linked with a symptom cluster
membership group were removed one at a time. Variables for which
the 95% confidence intervals contained one in all of the symptom
cluster groups were removed to ensure we had a parsimonious model.
The low symptom burden group was the reference group for
comparison with the other symptom groups.
Missing data in the LCA model were handled with full-information
maximum likelihood (FIML), an imputation method often used in LCA
and structural equation modeling. FIML imposes no bias for data
missing completely or missing at random and can be used with
categorical indicator variables (Enders & Bandalos, 2001). FIML is
superior to case-wise deletion, even when data are not missing at
TABLE 1 Demographic and clinical characteristics of the sample
(N = 5926)
M SD n %
Age (years) 44.13 15.19
Gender
Female 3,821 72.15
Male 1,475 27.85
Missing 0 0.00
Race/ethnicity
White non-hispanic 4,599 92.33
Other 382 7.67
Missing 315 5.95
Education n (%)
High school or less 369 6.97
Some college/college degree 2,934 55.40
Graduate school 1,536 29.00
Missing 457 8.62
Smoking status
Never 3,341 63.09
Ever 1,631 30.80
Current 316 5.97
Missing 8 0.15
Disease duration (years) 14.42 12.92
IBD diagnosis
Crohn's disease 2,992 56.50
Ulcerative colitis 1,803 34.04
Missing 501 9.46
Medications
5-ASAs 2,474 46.71
Corticosteroids 753 14.21
Immunomodulators 1,522 28.74
Biologics 1,839 34.72
Disease activity
Remission 2,835 53.53
Active disease 2,086 39.40
Missing 375 7.08
IBD, inflammatory bowel disease; 5-ASAs, 5-aminosalicyclic acids.
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random (Graham, 2009). Due to the limitations of FIML, we excluded
cases with missing covariate data, to mirror the approach used in
structural equation modeling (Collins & Lanza, 2010).
3 | RESULTS
The original CCFA Partners sample included 14,314 participants. We
excluded 1,846 who had j-pouches or ostomies or who did not indicate
presence or absence of either. We used symptom data from the second
CCFA survey (administered between 2012 and 2015) because pain
interference was not included in the baseline survey.We excluded 7,172
participants who did not complete the second survey. The final sample
included 5,296 participants. Excluded participants had a similar percent-
age with active disease (39.77% vs. 39.40%). However, they were, on
average, younger (M= 42.80 [SD = 14.68] vs. M = 44.13 years
[SD =15.19] years) and had shorter disease duration in years
(M = 13.90 [SD =12.23] vs M = 14.42 years [SD= 12.92]) than included
participants. Less than 10% of data were missing for the final sample.
Therefore, there was low risk of bias due tomissing data (Bennett, 2001).
3.1 | Demographics, clinical characteristics, and
symptoms
Table 1 includes the clinical and demographic characteristics of the
final sample. The mean age of participants was 44.13 years (SD 15.19,
range 18–89 years), and the majority of the sample were female
(72.15%) and non-Hispanicwhite (92.33%). Themean disease duration
was 14.42 years (SD = 12.92, range = 0–64 years).
All five symptoms were prevalent, with 54.06% of participants
reporting pain interference, 63.14% reporting fatigue, 59.23%
reporting sleep disturbance, 49.92% reporting depressive symptoms,
and 62.65% reporting anxiety. The prevalence of each symptom and
the associations of symptoms with disease activity are reported in
Table 2. The majority of participants reported two or more symptoms
(n = 3,884; 73.33%), while 13.27% (n = 703) reported one symptom,
TABLE 2 Comparison of symptom reports on disease activity (n = 5296)
Total sample Active disease (n = 2,086; 39.4%) Remissiona (n = 2,825; 53.3%)
Symptom n (%) n (%) n (%)
Pain
Yes 2,863 (54.06) 1,659 (31.33) 999 (18.9)
No 2,372 (44.79) 405 (7.65) 1,819 (34.35)
Fatigue
Yes 3,344 (63.14) 1,745 (32.95) 1,355 (25.58)
No 1,928 (36.40) 332 (6.27) 1,470 (27.76)
Sleep disturbance
Yes 3,137 (59.23) 1,540 (29.08) 1,374 (25.94)
No 2,101 (39.67) 527 (9.95) 1,442 (27.23)
Depression
Yes 2,644 (49.92) 1,411 (26.64) 1,032 (19.49)
No 2,647 (49.98) 674 (12.73) 1,799 (33.97)
Anxiety
Yes 3,318 (62.65) 1,591 (30.04) 1,478 (27.91)
No 1,976 (37.31) 494 (9.33) 1,356 (25.60)
Due to missing data, percentages do not add up to 100%. All group comparisons p < .001 in chi-square tests.
aScores of <150 on the Short Crohn's Disease Activity Index and ≤2 on the Simple Clinical Colitis Activity Index were defined as clinical remission.
TABLE 3 Latent class fit statistics for one to five latent classes of symptoms
Number of latent classes Log-likelihood G2 df AIC BIC
1 −17759.89 5206.58 26 5216.58 5249.45
2 −15499.39 685.57 20 707.57 779.89
3 −15280.48 247.75 14 281.75 393.52
4a −15160.26 7.31 8 53.31 204.52
5 −15157.84 2.46 2 60.46 251.13
AIC, Akaike information criterion; BIC, Bayesian information criterion.
aThe 4-class solution was selected because AIC and BIC were lowest.
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12.09% (n = 640) reported no symptoms, and 1.20% (n = 69) were
missing data on one or more symptoms.
3.2 | Symptom clusters
Participants were grouped into four distinct symptom clusters in LCA
based on the presence or absence of each of the symptoms.We selected
the four-class solutionbecause it had the lowestAICandBICstatistics and
was parsimonious and clinically relevant. The fit indices for all fivemodels
are shown in Table 3. The item-response probabilities for each of the four
symptom membership groups by symptom are shown in Table 4.
The first group was labeled “low symptom burden” and included
25.59% of the participants. It was characterized by a low probability of
experiencing pain, fatigue, sleep disturbance, depression, and anxiety.
The second and largest group (38.10% of the sample) was labeled “high
symptom burden” and was characterized by a high probability of
experiencing pain, fatigue, sleep disturbance, depression, and anxiety.
The third group, including 22.09% of participants, was labeled
“physical symptoms,” and was characterized by a high probability of
experiencing pain, fatigue, and sleep disturbance. The fourth group
“psychological symptoms,” was the smallest group at 14.22% and was
characterized by a high probability of experiencing anxiety and
depression.
3.3 | Demographic and clinical factors associated
with symptom cluster group membership
In developing the multivariable multinomial regression model, current
use of immunomodulators (p = .56), 5-ASA (p = .41), biologics (p = .06),
completion of some or all college (p =.06), or graduate school (p = .84)
compared to high school education or less, and race/ethnicity (p = .05)
were dropped in the above order because they were not statistically
associated with membership in any symptom cluster group. Younger
age, female gender, smoking history, IBD duration, current use of
corticosteroids, IBD type, and active disease status were included in
the final model. See Table 5 for the estimated odds ratios with 95%
confidence intervals for the associations between the demographic
and clinical characteristics, and symptom cluster membership.
Older age was associated with a small decrease in odds of
membership (based on magnitude of odds ratios as interpreted by
Chen, Cohen, and Chen (2010) in the psychological symptom cluster
group. Female gender and smoking history were associated with a
small increase in odds ofmembership in both the high symptomburden
and psychological symptom groups. Longer IBD duration was
associated with a small decrease in odds of membership the high
symptom burden group. Current use of corticosteroids and a diagnosis
of Crohn's disease compared to ulcerative colitis/indeterminate colitis
were associated with a medium increase in odds of being in the high
symptom burden group and the physical symptoms group. Remission
was associated with a medium (psychological symptom group) to large
decrease in odds (high symptom burden group and physical symptom
group) of being in the high symptom burden, physical, and
psychological symptom cluster groups.
4 | DISCUSSION
To our knowledge, this study was the first to identify symptom cluster
group membership among people with IBD. The findings suggest that
symptom burden is high among people with IBD, as demonstrated by
the fact that nearly 75% of the sample belonged to a symptom cluster
group characterized by at least two symptoms. This result suggests
that symptom management may be suboptimal in this population.
Although the full implications of the differences between the symptom
cluster groups are not known, there is a need to better understand the
etiology and consequences of symptom cluster groupmembership and
to consider differences in need for interventions based on symptom
cluster group membership. For example, interventions for those with
physical versus psychological symptoms are likely to differ. The high
symptom cluster burden group may have worse function (e.g., physical
function, social function, ability to work) and medical outcomes (e.g.,
need for surgery, hospitalizations); however, additional research is
needed to identify how these outcomes differ with symptom cluster
groupmembership. The clusters found in our study are consistent with
previous studies of adults with other common chronic inflammatory
conditions, including multiple sclerosis (Shahrbanian, Duquette,
Kuspinar, & Mayo, 2015), cancer (Miaskowski et al., 2015), and heart
failure (Lee et al., 2010).
Although remission is associated with decreased symptoms, our
finding that nearly half of those in remission reported at least one
symptom is consistent with previous research conducted with people
TABLE 4 Prevalence of class membership and response probabilities in four-class model of symptom clusters (N = 5296)
Low symptom burden High symptom burden Physical symptoms Psychological symptoms
Prevalence n = 1,355; 25.59% n = 2,018; 38.10% n = 1,170; 22.09% n = 753; 14.22%
Pain .12 .86 .66 .32
Fatigue .13 .96 .78 .46
Depression .04 .90 .23 .69
Anxiety .18 1.00 .27 1.00
Sleep disturbance .24 .84 .70 .45
Bold font indicates symptoms that characterize each class.
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with IBD (Bielefeldt, Davis, & Binion, 2009; Zhang et al., 2013).
Possible reasons for the persistence of symptoms may include
sub-clinical inflammation (Berrill, Green, Hood, & Campbell, 2013),
comorbid conditions such as rheumatoid arthritis and irritable bowel
syndrome (Ansari et al., 2008), or learned behavior (Kattoor et al.,
2013), but none of these variables were included in the CCFA Partners
surveys. Studies should be conducted to improve understanding of the
etiology of symptoms occurring during both active disease and
remission and the factors that may differentiate them.
Crohn's disease was associated with membership in the high
symptom burden and physical symptom groups. In contrast to our
findings, other researchers found no difference in sleep quality or
fatigue between people with Crohn's disease and ulcerative colitis
(Graff et al., 2011). Our findings suggest that Crohn's disease may be a
risk factor for high symptom burden and warrant focused symptom
assessment andmanagement. Additional research is needed to explore
the reasons for differences in symptom cluster membership that may
be modifiable. For example, nutritional status may differ between
Crohn's disease and ulcerative colitis and affect the symptom
experience (Bryant, Trott, Bartholomeusz, & Andrews, 2013).
Our finding that use of corticosteroids was associated with
membership in the high symptom burden and physical symptom
groups is consistent with previous findings of strong associations
between corticosteroid use and anxiety and depression (Loftus et al.,
2011). Our findings suggested people with IBD who took corticoste-
roids did not experience psychological symptoms alone but also
experienced physical symptoms. Although corticosteroids are often
used to treat active disease, the association between symptom cluster
membership and corticosteroids was not fully explained by remission
status, suggesting that any persons with IBD taking prescribed
corticosteroids may need symptom management.
Female gender was associated with higher odds of belonging to
the high symptom burden and psychological symptom cluster groups
compared to the low symptom burden cluster group, even with
remission taken into account. This result is consistent with previous
IBD research in which females were more likely to have more severe
symptoms compared to men (Ananthakrishnan et al., 2013; Bager
et al., 2012;Walker et al., 2008). Gender differences may be a result of
greater symptom awareness among females, differences in percep-
tions or reporting rates, or biological differences such as menstrual
cycle influences (Barsky, Peekna, & Borus, 2001; Racine et al., 2012).
These findings suggest a greater need for symptom management
among females, although gender differences need further study.
Smoking history was associated with membership in the high
symptom burden and the psychological symptom groups. The
relationship between smoking and IBD is complex and somewhat
contradictory. For example, smoking is associated with development
and worsening of Crohn's disease but protective against develop-
ment and worsening of ulcerative colitis (Birrenbach & Bocker, 2004;
Parkes et al., 2014). In past research, smoking history was associated
with anxiety but not depression among people with IBD (Nahon
et al., 2012). In the general population, a history of smoking is related
to anxiety and depression, nicotine dependence symptoms and
depressive symptoms are often comorbid (Mykletun, Overland, Aaro,
Liabo, & Stewart, 2008), and smoking may increase the risk of
depression (Boden, Fergusson, & Horwood, 2010). Our findings
suggest that former and current smokers need additional symptom
screening and symptom treatment, especially for psychological
symptoms.
While the odds ratio was small, we were surprised to find that
longer IBD duration was associated with decreased odds of member-
ship in the high symptom burden cluster group, even when controlling
for remission status and corticosteroid use. Although the reasons need
further study, people diagnosed with IBD may go through a period of
adjustment and adaptation (McCormick et al., 2012) in which they
establish new expectations and meanings regarding health (Cooper,
Collier, James, & Hawkey, 2010; Hall, Rubin, Dougall, Hungin, & Neely,
2005) and become accustomed to symptoms. Learning how to adapt to
IBD takes time and experience but becomes part of a normal life
(Cooper et al., 2010; Hall et al., 2005). Health care providers can
provide active support to IBD patients to help define expectations and
experiences to assist in this transition.
TABLE 5 Demographic and clinical factors associated with symptom cluster group membership (n = 4544)
High symptom burden Physical symptoms Psychological symptoms
Odds ratio (95%CI) Odds ratio (95%CI) Odds ratio (95%CI)
Age 0.99 (0.98, 1.00) 1.02 (1.00, 1.03) 0.99 (0.98, 0.99)
Female 2.46 (1.29, 2.27) 0.85 (0.59, 1.23) 1.33 (1.05, 1.66)
Ever smoker 1.71 (1.30, 2.24) 0.87 (0.62, 1.22) 1.32 (1.05, 1.66)
IBD duration (years) 0.98 (0.97, 0.99) 0.99 (0.97, 1.00) 1.00 (0.99, 1.01)
Corticosteroids
(yes/no)
3.99 (2.66, 5.99) 3.37 (2.09, 5.40) 1.51 (1.00, 2.27)
Crohn's disease 5.69 (3.81, 8.50) 6.33 (4.00, 10.11) 1.08 (0.86, 1.36)
Remission 0.11 (0.01, 0.02) 0.03 (0.02, 0.04) 0.23 (0.16, 0.38)
Results of multinomial regression analysis using backwards selection with symptom cluster membership as the outcome. Low symptom burden group was
used a reference group. Bold font indicates significant association.
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4.1 | Implications for future research
The etiology of symptom clusters in IBD is unknown. Researchers
suggested that symptom clusters in cancer may have a common
biological mechanism, including inflammatory cytokines (Cleeland
et al., 2003; Illi et al., 2012), hypothalamus-pituitary-adrenal axis (HPA)
dysfunction (Kim, Barsevick, Fang, & Miaskowski, 2012; Thornton,
Andersen, & Blakely, 2010), dysfunctional cognitions and behaviors
(Kroenke & Swindle, 2000), and catastrophizing cognitions (Somers
et al., 2009). It is possible that similar mechanisms are responsible for
symptoms in people with IBD, a condition that is also inflammatory in
nature. There is a need for evaluation of the associations of symptom
clusters with biomarkers, such as cytokines (Miaskowski & Aouizerat,
2012), fecal calprotectin (Vieira et al., 2009), and omics (e.g.,
inflammatory genes; Illi et al., 2012). This research will increase
understanding of the etiology of symptom clusters.
Because symptoms are associated with decreased ability to work
and participate in social activities, further research is needed to
understand better the full impact of symptom cluster membership on
multiple domains of quality of life, including ability to work, and social
functioning and health care utilization and costs. These studies will
support understanding of the consequences of symptom burden.
Subsequent research can follow to determine the effects of
interventions to improve symptom burden.
4.2 | Strengths and limitations
This study has several strengths, including the use of a well-
characterized cohort and a statistically robust method that is well-
suited for secondary data analysis of symptom clusters (Magidson &
Vermunt, 2003). The large sample enabled us to conduct a well-
identified LCA model, including consideration of several covariates.
Use of validated and standardized symptom measures will allow
comparison of the results with those of other studies in which these
measures were used.
Limitations of this study were the unidimensional nature of the
PROMIS measures and the need to dichotomize the symptoms to use
LCA. Therefore, we cannot infer severity of single symptoms,
frequency, or symptom-associated distress. Reliance on secondary
analysis precluded knowledge of participant characteristics that were
not collected in the surveys, such as participants’ disease location (e.g.,
ileum, rectum) or use of non-IBD medications (e.g., hypnotics,
antidepressants). Another limitation is that diarrhea and fecal
incontinence were not included as indicator variables in this study.
Diarrhea and fecal incontinence are the predominant signs (objective
indicators) of IBD. Diarrhea is a primary indicator in the disease activity
indices that were used as a covariate but cannot be teased out of the
disease activity indices, as they were not measured consistently
between Crohn's disease and ulcerative colitis. Future research is
needed to further explore the significance of these signs in IBD. Last,
although the use of the internet for data collection allowed a broad
geographic representation, it may have limited the racial and ethnic
diversity of the sample, which had an overrepresentation of highly
educated, non-Hispanic white females. Therefore, the results cannot
be generalized to groups that were underrepresented in this cohort.
5 | CONCLUSION
People with IBD experience high symptom burden. Younger age,
female gender, current or past smoking, IBD duration, current use of
corticosteroids, Crohn's disease, and remission status were associated
with symptom burden. Future research will focus on biomarkers and
genetic factors associated with symptom clusters and on the impact of
symptom clusters on work and social functioning, health care resource
utilization, and costs of health care. In the meantime, healthcare
providers should assess for the presence of symptom clusters and offer
symptom management where needed.
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